Fitt Insider Peptides, Performance Retail, and Fitness Wearables
4 snips
Feb 19, 2026 Discussion of a weight-loss drug showing 30% results and its potential market impact. Conversation about early adopters like bodybuilding and Hollywood and the regulatory risks involved. A retail-meets-studio pop-up blending workouts, Pilates and run clubs. Report on record wearables revenue and rising fitness tech demand.
AI Snips
Chapters
Transcript
Episode notes
Meet Up At The Connected Health Summit
- If you're attending the Connected Health & Fitness Summit, email team@fitt.co to meet Joe Venneri.
- He'll host a fireside chat on AI in fitness and the anticipated $7.5B EGYM merger.
Retatrutide Reframes Weight-Loss Drugs
- Retatrutide could expand weight-loss drugs into performance and body-composition territory.
- Andrew Huberman called it a potential trillion-dollar drug after Phase III showed up to 30% weight loss with muscle preservation.
Peptides Adopted For Performance
- Early adopters include bodybuilders and Hollywood using peptides for performance and physique.
- If approved, retatrutide may compete with GLP-1s and broaden the metabolic performance category.